CompletedPhase 2

Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers

LY2062430: Multiple-Dose Safety in Subjects With Mild-to-Moderate Alzheimer's Disease and Single-Dose Safety in Healthy Volunteers

Lead sponsor

Eli Lilly and Company

Asset

Solanezumab

Listed sites

Recruiting sites

Enrollment

actual

Study population

Alzheimer’s disease

Key I/E criteria

•mild-to-moderate AD•Study partner/caregiver required•Healthy volunteers

Primary endpoint

•Safety and tolerability

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study ID6649

SecondaryH8A-MC-LZAJ

NCT IDNCT00329082

Timeline

Milestones

Study start2006-05 (month precision)

Study first posted2006-05-24estimated

Primary completion2008-05actual (month precision)

Study completion2008-05actual (month precision)

Last update posted2009-10-07estimated

Assets

Drug assets

Solanezumab

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age50 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•At least 50 years of age and diagnosed with mild to moderate Alzheimer's disease or healthy volunteers

•fluent in reading and speaking English

•AD patients must have a reliable study partner who will be in frequent contact with the patient and comply with protocol requirements

•AD patients who have received AChEIs or memantine for at least 4 months and on stable therapy for at least 2 months prior to starting study drug

Exclusion criteria

•Have a history of serious infectious disease affecting the brain, head trauma, cancer, drug or alcohol abuse in the past 5 years

•Have serious or uncontrolled health problems or laboratory tests

•Multiple or severe drug allergies

•Prior participation in an active immunization study

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK

Memory

Amyloid biomarkers

Memory

1 endpoint

Secondary/protocol endpoint

To evaluate the changes in thinking and memory

Time frame:1 year

descriptive

Amyloid biomarkers

1 endpoint

Secondary/protocol endpoint

To evaluate the pharmacokinetic/pharmacodynamic relationships between LY2062430 concentrations and plasma peptide amyloid beta concentrations

Time frame:1 year

concentration, descriptive

Safety / tolerability / PK

2 endpoints

Primary/protocol endpoint

Safety and tolerability

Time frame:1 year

descriptive

Secondary/protocol endpoint

To determine the plasma pharmacokinetics of LY2062430

Time frame:1 year

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.